Parkman Healthcare Partners LLC Takes Position in ARS Pharmaceuticals, Inc. $SPRY

Parkman Healthcare Partners LLC acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the second quarter, Holdings Channel.com reports. The firm acquired 102,700 shares of the company’s stock, valued at approximately $823,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Torren Management LLC bought a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $32,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after purchasing an additional 982 shares during the last quarter. Bessemer Group Inc. raised its position in shares of ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock valued at $61,000 after purchasing an additional 7,290 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $65,000. Finally, Russell Investments Group Ltd. raised its position in shares of ARS Pharmaceuticals by 197.5% in the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares during the period. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $5.35 on Tuesday. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72. The business’s 50 day moving average is $7.15 and its two-hundred day moving average is $8.11. The company has a market cap of $532.04 million, a P/E ratio of -2.45 and a beta of 0.98. ARS Pharmaceuticals, Inc. has a 12 month low of $4.91 and a 12 month high of $14.00.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%.The business had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. On average, equities analysts expect that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current year.

Insiders Place Their Bets

In related news, insider Eric Karas sold 25,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the transaction, the insider owned 12,176 shares of the company’s stock, valued at approximately $121,760. The trade was a 67.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $33,550.00. Following the transaction, the insider owned 90,910 shares of the company’s stock, valued at approximately $909,100. The trade was a 3.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 33.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SPRY shares. Weiss Ratings downgraded shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Leerink Partners lowered their target price on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Thursday, June 25th. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Cantor Fitzgerald boosted their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.